Tazarotene plus UVB phototherapy in the treatment of psoriasis

Koo, John; Lowe, Nicholas J.; Lew‐Kaya, Deborah A.; Vasilopoulos, Alexandra I.; Lue, John C.; Sefton, John; Gibson, John R.

doi:10.1067/mjd.2000.107940

Cited by 83 publications

(46 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The combination of tazarotene (0.1%) gel once daily with UVB phototherapy 3 times per week proved to be very effective [60]. The addition of tazarotene proved to accelerate the efficacy substantially, whilst reducing the median cumulative UVB exposure to achieve at least 50% improvement from the pretreatment baseline [61].…”

Section: Combinationsmentioning

confidence: 98%

The Topical Treatment of Psoriasis

Kerkhof

Vissers

2003

Skin Pharmacol Physiol

View full text Add to dashboard Cite

According to the patients, improvement of efficacy, long-term safety and improvement of compliance are needed. The topical treatment has been innovated during the last decade. Most important are the introduction of two new classes of treatments: topical vitamin D₃ analogues and the retinoid tazarotene. To what extent, however, have we achieved developments which are in line with the needs as expressed by the patients? Improved efficacy has been realized by successful combinations of topical treatments. In particular, the combinations of dithranol, vitamin D₃ and tazarotene with a topical corticosteroid proved to be very effective with a reduced profile of side-effects. The efficacy of vitamin D₃ analogues and tazarotene is such that the efficacy of a potent corticosteroid (betamethasone-17-valerate) is approached; calcipotriol even showed an efficacy which is at least as good as this corticosteroid. The long-term safety of new compounds has been evaluated for at least 12 months in large studies. Remarkably for corticosteroids such information is available for only 12 weeks. However, intermittent applications of a topical corticosteroid in combination with another topical treatment provide an effective and safe long-term control of psoriasis. Compliance is a conditio sine qua non for an effective topical treatment. Important progress has been made to increase compliance. Short-contact dithranol has been popularized as an ambulatory treatment which is a highly effective approach as a care instruction programme. Formulations which are better from a cosmetical point of view have been developed for various topical treatments. Reduction of the frequency of applications proved to be possible for most treatments. Once daily applications for corticosteroids, vitamin D₃ analogues and retinoids have been developed, and intermittent applications, a few times per week, are possible for corticosteroids, which proved to be very effective with a reduced profile of side-effects, and are also developed for dithranol.

show abstract

Section: Combinationsmentioning

confidence: 98%

The Topical Treatment of Psoriasis

Kerkhof

Vissers

2003

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…34 Tazarotene combined with either broadband or narrowband UVB was shown to be more effective than UVB alone and to decrease total UVB exposure. 35,36 Tazarotene is photostable with both UVA and UVB. 37 However, 2-week course of tazarotene decreases the minimal erythema dose of UVB by about 25% and the UVA dose required to induce immediate pigment darkening by about 8%.…”

Section: Tazarotenementioning

confidence: 99%

Topical Agents for the Treatment of Psoriasis, Past, Present and Future

Tremblay¹,

Bissonnette²

2002

Journal of Cutaneous Medicine and Surgery: Incorporating Medica

View full text Add to dashboard Cite

“…Most importantly, tazarotene significantly reduced the amount of UV radiation required to improve psoriasis: in combination therapy with tazarotene, the median cumulative UVB exposure was 390 mJ/cm 2 , while it was approximately 4 times higher (i.e. 1,644 mJ/cm 2 ) in UVB monotherapy [27]. Considering the potential long-term hazards of UVB and PUVA treatment like accelerated skin aging and an increased risk of cutaneous cancer [28,29], the adjunctive use of tazarotene results in a decrease in total doses of UVB or PUVA which might reduce treatment hazards.…”

Section: Treatment Strategiesmentioning

confidence: 99%

Tazarotene: Therapeutic Strategies in the Treatment of Psoriasis, Acne and Photoaging

Roeder

Schaller

Schäfer‐Korting

et al. 2004

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination treatments and a comparison of different agents for these skin disorders are accumulating. The concomitant use of tazarotene with a mid-potency or high-potency corticosteroid enhances the efficacy in psoriatic plaques and reduces the risk of steroid-induced skin atrophy. Combining phototherapy with adjunctive tazarotene accelerates the clinical response and reduces the cumulative UVB or PUVA exposure load. Tazarotene applied once daily is superior to adapalene monotherapy in acne vulgaris and is efficacious in the treatment of photodamage. Novel therapeutic regimens such as short-contact therapy have been developed for both acne and psoriasis in order to diminish the major adverse events like pruritus, burning, local skin irritation and erythema.

show abstract

Tazarotene plus UVB phototherapy in the treatment of psoriasis

Cited by 83 publications

References 13 publications

The Topical Treatment of Psoriasis

The Topical Treatment of Psoriasis

Topical Agents for the Treatment of Psoriasis, Past, Present and Future

Tazarotene: Therapeutic Strategies in the Treatment of Psoriasis, Acne and Photoaging

Contact Info

Product

Resources

About